• PDB61 CHART AUDIT OF THE DOSE AND EFFECTIVENESS OF LONG ACTING INSULIN ANALOGUES IN AUSTRALIAN CLINICAL PRACTICE

    Nov 1, 2008, 00:00

  • PDB49 HEALTH-RELATED QUALITY OF LIFE (HRQOL) AND TREATMENT SATISFACTION (TS) IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PSY39 IMPACT OF HIGHWAIST CIRCUMFERENCE ON PRODUCTIVITY IN US AND GERMAN OVERWEIGHT/OBESE SUBJECTS

    Nov 1, 2008, 00:00

  • PRS4 SUB-ACUTE LACK OF ASTHMA CONTROL AS A PREDICTOR OF ASTHMA EXACERBATION IN A MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PSS24 SYSTEMATIC REVIEW AND META-ANALYSIS OF RCTS REGARDING THE COMPARATIVE INCIDENCE OF HYPERAEMIA OF PROSTAGLANDIN TOPICAL GLAUCOMA MEDICATIONS

    Nov 1, 2008, 00:00

  • PCV109 PRESCRIPTION DRUG INSURANCE AND EX ANTE MORAL HAZARD

    Nov 1, 2008, 00:00

  • PG139 ALEGRIA, A REAL LIFE EVALUATION OF GERD (GASTROESOPHAGEAL REFLUX DISEASE) IMPACT OF SYMPTOM ASSESSMENT IN LUXEMBOUR

    Nov 1, 2008, 00:00

  • PRS30 HOW CONGRUENT ARE PATIENT AND CLINICIAN MODELS OF ASTHMA CONTROL?-PRELIMINARY FINDINGS FROM A QUALITATIVE STUDY

    Nov 1, 2008, 00:00

  • PCV69 COST-EFFECTVENESS OF ENDOVASCULAR ANEURYSM REPAIR VERSUS OPEN SURGICAL REPAIR- NON-RUPTURED INFRARENAL ABDOMINAL AORTIC ANEURYSM IN AN ELECTIVE SETTING

    Nov 1, 2008, 00:00

  • PSY29 TREATMENT COST OF FEBRILE NEUTROPENIA (FN) IN PATIENTS WITH ACUTE LEUKEMIA (AL) OR IN AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT) RECIPIENTS FROM THE GERMAN HOSPITALS PERSPECTIVE

    Nov 1, 2008, 00:00

  • PHP40 INVESTIGATING THE PROMOTION OF HEALTH BEHAVIOR AND HEALTH-RELATED QUALITY OF LIFE BY APPLYING SELF-DETERMINATION THEORY- USING 'EXERCISE' AS AN EXAMPLE

    Nov 1, 2008, 00:00

  • PMH61 ADULTS WITH ATTENTION-DEFICIT/ HYPERACTIVITY DISORDER (ADHD) IN GERMANY-PREVALENCE, COMORBIDITIES AND PHARMACOTHERAPY IN PRACTICE

    Nov 1, 2008, 00:00

  • PMS66 WILLINGNESS TO PAY VS. QUALITY ADJUSTEDWAGES AS ALTERNATIVE WAYS TO MEASURE THE BURDEN OF DISEASE IN SPAIN- AN APPLICATION TO BALLOON KYPHOPLASTY

    Nov 1, 2008, 00:00

  • PHP59 LABEL CLAIMS BASED ON PATIENT REPORTED OUTCOMES IN EMEA AND FDA APPROVALS SINCE 2000

    Nov 1, 2008, 00:00

  • PSS49 A DISEASE MODEL ILLUSTRATING THE IMPACT OF PSORIASIS ON PATIENTS LIVES

    Nov 1, 2008, 00:00

  • PSY25 SYSTEMATIC REVIEW OF THE COST OF ILLNESS OF SYSTEMIC LUPUS ERYTHEMATOSUS

    Nov 1, 2008, 00:00

  • PMC61 THE IMPLICIT VALUE OF STATISTICAL LIFE- ESTIMATES DERIVED FROM PUBLIC INTERVENTIONS IMPLEMENTED IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMH42 HEALTH-RELATED QUALITY OF LIFE OF MARRIED, WORKING WOMEN WITH CHILDREN (SUPERWOMAN SYNDROME) IN KOREA

    Nov 1, 2008, 00:00

  • PDB29 ESTIMATING THE DIRECT COST OF TYPE II DIABETES IN GREECE

    Nov 1, 2008, 00:00

  • PIN3 A SIMULATION-BASED APPROACH TO MODELING THE EFFECTS OF INTERVENTION STRATEGIES ON THE SPREAD OF MENINGOCOCCAL MENINGITIS

    Nov 1, 2008, 00:00

  • PHP31 IS PATENT PROTECTION CREATING OPPORTUNITY FOR INNOVATION?-THE ALENDRONATE CASE IN BELGIUM

    Nov 1, 2008, 00:00

  • PHP35 PHARMACEUTICAL EXPENDITURE IN GREECE 1980-2006

    Nov 1, 2008, 00:00

  • PCV11 EFFECTIVENESS OF DRUG-ELUTING STENTS VS. BARE METAL STENTS UNRESTRICTED USE IN PATIENTS WITH CORONARY HEART DISEASE IN SOCIAL SECURITY MEXICAN INSTITUTE

    Nov 1, 2008, 00:00

  • PHP42 EVALUATION OF THE AFTERNOON OUTPATIENT CLINICS OPERATION AT THE UNIVERSITY HOSPITAL IN LARISA

    Nov 1, 2008, 00:00

  • PUK4 PHARMACOECONOMIC EVALUATION OF SOLIFENACIN IN THE TREATMENT OF OVERACTIVE BLADDER SYNDROME IN ITALY

    Nov 1, 2008, 00:00

  • PMH32 A GPRD STUDY OF HEALTH CARE COST ASSOCIATED WITH DIFFERENT FIRST-LINE ANTIDEPRESSANT TREATMENTS IN SEVERE DEPRESSION

    Nov 1, 2008, 00:00

  • PCV92 DERIVING UTILITY VALUES FOR ACUTE CORONARY SYNDROMES FROM THE GENERAL POPULATION IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PDB27 INSULIN GLARGINE AND NPH INSULIN-BASED REGIMENS REVEAL COMPARABLE TOTAL DIRECT TREATMENT COSTS IN TYPE 2 DIABETES PATIENTS.THE LONG-ACTING INSULIN GLARGINE VS. NPH INSULIN COST EVALUATION STUDY IN GERMANY (LIVE-DE)

    Nov 1, 2008, 00:00

  • PCN51 POTENTIAL ECONOMIC AND HEALTH IMPACT OF GENOMICS AND PROTEOMICSTECHNOLOGY FOR THE TREATMENT OF ACUTE MYELOID LEUKEMIA

    Nov 1, 2008, 00:00

  • PSS53 A TOPIC DERMATITIS IN PAEDIATRIC PATIENTS- COMMON CAREGIVER BEHAVIOURWHEN FACING THE DIFFERENT DISEASE PRESENTATIONS OR LESION SEVERITY. ELIBROT STUDY

    Nov 1, 2008, 00:00

  • PCN47 ECONOMIC EVALUATION IN THE POSTOPERATIVE MANAGEMENT OF COLORECTAL CANCER PATIENTS IN GREECE

    Nov 1, 2008, 00:00

  • PND29 EFFICIENCY PROFILE IN THE NEUROLOGICAL REFERRALS EFFECTUATE REFERENCE SPECIALISTS- USE CASE-MIX SYSTEM ADJUSTED CLINICAL GROUPS

    Nov 1, 2008, 00:00

  • PMC50 THE SUITABILITY OF VISUAL ANALOGUE SCALES (VAS) FOR COLLECTING PATIENT-REPORTED OUTCOMES (PRO) DATA FROM INTERNATIONAL SETTINGS

    Nov 1, 2008, 00:00

  • PRS15 ESTIMATING EXCESS COSTS OF POPULATION-BASED CASES WITH MILD COPD-RESULTS FROM THE KORA F3 STUDY

    Nov 1, 2008, 00:00

  • PUK20 VALIDATION OF THE SPANISH VERSION OF THE PELVIC ORGAN PROLAPSE/URINARY INCONTINENCE SEXUAL QUESTIONNAIRE-SHORT FORM (PISQ-12)

    Nov 1, 2008, 00:00

  • QL10 DEVELOPMENT AND VALIDATION OF THE SATISFACTION WITH MEDICATION QUESTIONNAIRE (SAT-Q) IN PATIENTS WITH CHRONIC DISEASE

    Nov 1, 2008, 00:00

  • PCV108 RISK AND COSTS OF THE FIRST HYPERTENSION-ASSOCIATED EVENT, COMPLIANCE AND PERSISTENCE IN NAVE HYPERTENSIVE PATIENTS AFTER INITIATING MONOTHERAPY

    Nov 1, 2008, 00:00

  • PND23 RELATIONSHIP BETWEEN CHANGES IN EQ-5D DERIVED UTILITY SCORES AND CHANGES IN IRLS SUM SCORES FROM A MAPPING EXERCISE IN TWO PHASE III CLINICAL TRIALS

    Nov 1, 2008, 00:00

  • PCV114 SEARCHING THE OPTIMAL TREATMENT MIX STRATEGY WITH A TREATMENT MIX CHART APPROACH-THE CASE OF CHOLESTEROL LOWERING IN SWEDEN

    Nov 1, 2008, 00:00

  • PUK16 EXPLORING THE IMPACT OF CHANGES IN NEUROGENIC URINARY INCONTINENCE FREQUENCY AND CONDITION SPECIFIC QUALITY OF LIFE ON PREFERENCE-BASED OUTCOMES

    Nov 1, 2008, 00:00

  • PMH40 PATIENTS WITH ATTENTION DEFICIT/HYPERACTIVITY DISORDER 2-YEAR ASSESSMENT OF IMPACT ON QUALITY OF LIFE AND CLINICAL SEVERITY- RESULTS FROM ADORE STUDY IN FRANCE

    Nov 1, 2008, 00:00

  • PHP54 ANTIBIOTICS CONSUMPTION IN THE REPUBLIC OF SERBIA IN 2004, 2005, 2006 AND 2007

    Nov 1, 2008, 00:00

  • PCN95 POLICY-MAKING FOR EXPENSIVE INNOVATIVE DRUGS IN FRANCE- ECONOMIC IMPACT AND INFLUENCE ON STAKEHOLDERS! BEHAVIOURS OF POTENTIAL DECISIONS ABOUT TAXANES

    Nov 1, 2008, 00:00

  • PDB11 POTENTIAL IMPACT OF LIPID CONTROL AND SUBSEQUENT CARDIOVASCULAR (CV) RISK REDUCTION INT2DM POPULATION TREATED WITH ORAL COMBINATION THERAPY (OCT) RECAP-DM STUDY

    Nov 1, 2008, 00:00

  • PIN16 COST-EFFECTIVENESS OF A PROPHYLACTIC HUMAN PAPILLOMA VIRUS 16/18 VACCINE FOR 12-YEAR-OLD DUTCH GIRLS

    Nov 1, 2008, 00:00

  • PMH20 ECONOMIC EVALUATION OF PALIPERIDONE ER FOR THE TREATMENT OF SCHIZOPHRENIA IN THE CONTEXT OF BRAZILIAN PUBLIC HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • PMS5 PREVALENCE OF FIBROMYALGIA IN GERMANY

    Nov 1, 2008, 00:00

  • PRS8 TOTAL COSTS OF TOBACCO FOR SOCIETY-WHAT ARE THE RETURNS ON INVESTMENTS FOR DIFFERENT GOVERNMENTAL INTERVENTIONS?

    Nov 1, 2008, 00:00

  • PCV88 IMPACT OF SINGLE-PILL VS. 2-PILL AMLODIPIN/ATORVASTATIN TREATMENT ON COMPLIANCE- A CZECH PILOT PROJECT ON MEDICATION ADHERENCE

    Nov 1, 2008, 00:00

  • PSY63 PATIENT-REPORTED OUTCOMES (PROS) AND ECONOMICS OF NEUROPATHIC PAIN IN GERMANY

    Nov 1, 2008, 00:00

  • PND20 MEASURING THE IMPACT OF NARCOLEPSY ON QUALITY OF LIFE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PHP8 ADVERSE DRUG REACTIONS IN GERMANY- COST ANALYSIS OF INTERNAL MEDICINE HOSPITALIZATIONS

    Nov 1, 2008, 00:00

  • PMS11 PREVALENCE OF FIBROMYALGIA IN RUSSIA- EARLY RESULTS

    Nov 1, 2008, 00:00

  • MH2 THE SUSTAINED DIAGNOSIS OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER FROM CHILDHOODTO ADULTHOOD- A MEDICAID STUDY

    Nov 1, 2008, 00:00

  • PMC54 THE RIGOUR, FLEXIBILITY AND EASE OF IMPLEMENTATION OF SYSTEMATIC SEARCH STRATEGIES-DOWE NEED AN INDUSTRY STANDARD METHODOLOGY?

    Nov 1, 2008, 00:00

  • DB2 IMPACT OF OVERWEIGHT OR OBESITY ON TREATMENT COSTS IN PATIENTS WITH DIABETES IN THE USA- QUANTILE REGRESSION APPROACH

    Nov 1, 2008, 00:00

  • PCN99 AVAILABILITY AND SPATIAL DISTRIBUTION OF ONCOLOGY SPECIFIC RESOURCES IN GREECE

    Nov 1, 2008, 00:00

  • PDB48 NOT ALL ROADS LEAD TO ROME-A REVIEW OF QUALITY OF LIFE MEASUREMENT IN DIABETES

    Nov 1, 2008, 00:00

  • PIH15 HEALTH-RELATED QUALITY OF LIFE IN ADOLESCENTS WITH THE PRADER-WILLI SYNDROME

    Nov 1, 2008, 00:00

  • PMS28 COST OF RHEUMATOID ARTHRITIS MODEL PER LEVEL OF DISEASE ACTIVITY IN FRANCE

    Nov 1, 2008, 00:00

  • PSY60 PREDICTING FACTORS FOR METABOLIC SYNDROME AMONG US ADOLESCENTS 12-17YEARS OF AGE

    Nov 1, 2008, 00:00

  • PHP5 HEALTH LITERACY-AN ECONOMIC PERSPECTIVE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PMH47 QUANTIFYING UNMET NEEDS AMONG PATIENTS WITH DEPRESSION USING AN SSRI OR SNRI ACROSS FIVE EUROPEAN COUNTRIES USING PATIENT-REPORTED SURVEY DATA

    Nov 1, 2008, 00:00

  • CN6 COST-EFFECTIVENESS OF A HUMAN PAPILLOMAVIRUS VACCINE IN REDUCING THE RISK OF CERVICAL CANCER IN IRELAND USING ATRANSMISSION DYNAMIC MODEL

    Nov 1, 2008, 00:00

  • PCN81 CROSS-CULTURAL ADAPTATION INTO SPANISH AND ITEM REDUCTION OF THE UCLA-PROSTATIC CANCER INDEX (UCLA-PCI)- A SPECIFIC HEALTH RELATED QUALITY OF LIFE (HRQOL) QUESTIONNAIRE FOR PROSTATIC CANCER

    Nov 1, 2008, 00:00

  • PCV102 COST-EFFECTIVENESS OF MANAGING ORAL ANTICOUAGULATION (OAC) AFTER CATHETER ABLATION FOR A TRIAL FIBRILLATION (PAAF) WITH IMPLANTABLE CARDIAC MONITORS (ICMS)

    Nov 1, 2008, 00:00

  • PHP50 UNIVERSAL STEPS IN PERFORMING EARLY-STAGE MEDICAL TECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PSS18 SENSITIVE SKINS IN SWITZERLAND- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PDB66 INSULIN GLARGINE UTILIZATION IN REAL-LIFE-EFFICACY OF A REGIMEN BASED ON INSULIN GLARGINE IN PATIENTS WITH TYPE 2 DIABETES PREVIOUSLY ON NPH INSULIN IN CLINICAL PRACTICE IN SPAIN

    Nov 1, 2008, 00:00

  • PIN2 ASSESSING ANTIMICROBIAL SUCCESS RATES IN THE TREATMENT OF METHICILLIN-RESISTANT STAPHYLOCOCCUS AUREUS (MRSA) COMPLICATED SKIN AND SOFT TISSUE INFECTIONS (CSSTI)-A BAYESIAN META-ANALYSIS

    Nov 1, 2008, 00:00

  • MS1 PREVALENCE OF FIBROMYALGIA IN EUROPE- A TIP OF THE ICEBERG.RESULTS FROM A LARGE-SCALE SURVEY

    Nov 1, 2008, 00:00

  • PDB50 CONCEPTUAL DEVELOPMENT OF A PATIENT SELF-ASSESSMENT TOOL TO IMPROVE PATIENT-CLINICIAN COMMUNICATION ON THE DAILY MANAGEMENT OF TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PCV7 CLINICAL EFFECTIVENESS OF BOSENTAN, EPOPROSTENOL, ILOPROST, SILDENAFIL AND TREPROSTINIL IN THE TREATMENT OF PULMONARY ARTERIAL HYPERTENSION-A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCN77 DERIVING UTILITY VALUES FROM THE GENERAL POPULATION FOR INDUCTION CHEMOTHERAPY ADMINISTERED BEFORE CONCURRENT CHEMOTHERAPY-RADIATION THERAPY IN THE TREATMENT OF HEAD AND NECK CANCER

    Nov 1, 2008, 00:00

  • PCN104 A BUDGET IMPACT MODEL FOR THE INTRODUCTION OF PANITUMUMAB, A NEWTHERAPY FOR THE MANAGEMENT OF METASTATIC COLORECTAL CANCER (MCRC) IN GREECE

    Nov 1, 2008, 00:00

  • PIN44 IMPACT OF ETRAVIRINE ON HOSPITALIZATIONS AND HOSPITAL RELATED COSTS IN BELGIUM- 48-WEEK FINDINGS FROM POOLED DUETTRIALS

    Nov 1, 2008, 00:00

  • PIN39 INPATIENT COSTS AND OUTCOMES ASSOCIATED WITH HEPATITIS C, HUMAN IMMUNODEFICIENCY VIRUS, AND CO-INFECTION WITH BOTH IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PCV6 EFFECTIVENESS OF CLOPIDOGREL IN ADDITION TO ASPIRIN COMPARED TO ASPIRIN ALONE AFTER ACUTE CORONARY SYNDROME

    Nov 1, 2008, 00:00

  • PCN66 HOW COSTLY IS RADIOTHERAPY WITH PARTICLES? COST ANALYSIS OF EXTERNAL BEAM RADIOTHERAPY WITH CARBON IONS, PROTONS AND CONVENTIONAL PHOTONS

    Nov 1, 2008, 00:00

  • PG115 COSTS OF CROHNS DISEASE WITHIN THE GERMAN STATUTORY HEALTH INSURANCE

    Nov 1, 2008, 00:00

  • PG118 DIRECT MEDICAL COSTS OF CROHNS DISEASE IN SPAIN- A MARKOV MODEL

    Nov 1, 2008, 00:00

  • PMH59 MODELLING THE ANTIDEPRESSANTS MARKET BEHAVIOUR AFTER PATENT EXPIRIES

    Nov 1, 2008, 00:00

  • PMH26 ONE YEAR PROSPECTIVE HEALTH CARE AND NON-HEALTH CARE RESOURCES USE AND COST STUDY IN PATIENTS WITH DEMENTIA OF ALZHEIMER TYPE- A SPANISH PERSPECTIVE

    Nov 1, 2008, 00:00

  • PRS14 COST OF ALLERGIC RHINITIS IN PEDIATRIC PATIENTS IN MEXICO

    Nov 1, 2008, 00:00

  • PMC39 WHAT DOES ACCEPTABILITY MEAN FOR PATIENTS AND HOW SHOULD IT BE MEASURED? QUALITATIVE STEPS FOR THE DEVELOPMENT OF A NEW MEASUREMENT INSTRUMENT IN PHARMACIES

    Nov 1, 2008, 00:00

  • PRS20 SYSTEMATIC REVIEW OF FIXED-DOSE COMBINATIONS AND UNIT-OF-USE PACKAGING IN PATIENTS WITH HYPERTENSION, DYSLIPIDEMIA, AIDS, ASTHMA AND DIABETES TYPE 2

    Nov 1, 2008, 00:00

  • PCV62 THE BURDEN OF ACUTE CORONARY SYNDROMES IN AUSTRALIA

    Nov 1, 2008, 00:00

  • PDB63 EFFECTS OF DOSING REGIMEN ON RESOURCE UTILIZATION AND COSTS IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2008, 00:00

  • PSY20 THE COST EFFECTIVENESS OF DULOXETINE IN THE TREATMENT OF FIBROMYALGIA IN THE NHS IN SCOTLAND

    Nov 1, 2008, 00:00

  • PHP16 OUTHOSPITAL DRUG CONSUMPTION IN MONTENEGRO IN 2007

    Nov 1, 2008, 00:00

  • PHP56 IMPACT OF ICU SEDATION PRACTICE ON PATIENT MORBIDITY, COST AND HOSPITAL RESOURCE USE- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PCV81 AN ECONOMIC EVALUATION OF THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY IN TERMS OF OPTIMAL LIPID VALUE ATTAINMENT

    Nov 1, 2008, 00:00

  • PIN43 DIFFERENCE IN HEALTH CARE UTILIZATION IN EUROPE BETWEENTREATMENT-NAVE PATIENTS WITH CHRONIC HEPATITIS C AND PATIENTSWHO FAILED PRIOR THERAPY

    Nov 1, 2008, 00:00

  • PSS40 RESPONSE SHIFT IN A RANDOMIZED CONTROLLED TRIAL OF LOWVISION CARE FOR PATIENTS WITH AGE-RELATED MACULOPATHY

    Nov 1, 2008, 00:00

  • PMH4 EFFICACY AND SAFETY OF ORAL A TYPICAL ANTIPSYCHOTICS FOR SCHIZOPHRENIA- A META-ANALYSIS INCLUDING PALIPERIDONE EXTENDED-RELEASE

    Nov 1, 2008, 00:00

  • PIN53 PHARMACY-IMPLEMENTED GUIDELINES ON SWITCHING FROM INTRAVENOUSTO ORAL ANTIBIOTICS- A PROSPECTIVE STUDY IN A TEACHING HOSPITAL

    Nov 1, 2008, 00:00

  • PCV105 STATIN PRESCRIBING IN THE CITY OF ZAGREB (2001-2006) AND THEIR ROLE IN SECONDARY PREVENTION OF CARDIOVASCULAR EVENTS

    Nov 1, 2008, 00:00

  • PCV40 COST-EFFECTIVENESS OF TARGETING MULTIPLE LIPID PARAMETERS (LDL-C, HDL-C, TG) WITH NIASPANVERSUS A SINGLE LIPID PARAMETER (LDL-C) WITH ZETIA IN PATIENTS RECEIVING ON-GOING STATIN THERAPY

    Nov 1, 2008, 00:00

  • CASE3 A CHANGE IN REIMBURSEMENT STRATEGY IN ICELAND- AIMING AT VALUE-BASED PRICING

    Nov 1, 2008, 00:00

  • PIN55 COST-EFFECTIVENESS OF DARUNAVIR/RITONAVIR 600/100MG BID IN TREATMENT-EXPERIENCED, LPV/R-NAVE, PI-RESISTANT, HIV-INFECTED ADULTS IN THE UNITED KINGDOM, BELGIUM, ITALY AND SWEDEN

    Nov 1, 2008, 00:00

  • MD1 HEALTH ECONOMIC ANALYSIS OF CONTINUOUS SUBCUTANEOUS INSULIN INFUSION COMPARED TO MULTIPLE DAILY INJECTIONS FOR THE TREATMENT OF TYPE 1 DIABETES IN POLAND

    Nov 1, 2008, 00:00

  • PMS43 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY REDUCES TIME LOST FROM WORK FOR PATIENTS WITH RHEUMATOID ARTHRITIS- POOLED RESULTS FROMTHREE PHASE 3 STUDIES

    Nov 1, 2008, 00:00

  • PG11 THE DEVELOPMENT AND PERFORMANCE OF MODELS TO PREDICT RISK OF LIVER DISEASE DIAGNOSIS FOLLOWING LIVER FUNCTION TESTING IN PRIMARY CARE

    Nov 1, 2008, 00:00

  • PRS38 DEVELOPMENT OF EXPLICIT APPROPRIATENESS CRITERIA FOR THE INDICATION OF ADMISSION FROM PATIENTS WITH ACUTE COPD EXACERBATION

    Nov 1, 2008, 00:00

  • PSY18 COST-EFFECTIVENESS OF FENTANYL ITS (IONSYSTM) IN POST-OPERATIVE PAIN MANAGEMENT- A FINNISH HOSPITAL PERSPECTIVE ANALYSIS

    Nov 1, 2008, 00:00

  • PMS16 ADALIMUMAB, ETANERCEPT AND INFLIXIMAB FOR THE TREATMENT OF ANKYLOSING SPONDYLITIS-BUDGET IMPACT ANALYSIS ON POLISH NATIONAL HEALTH FUND

    Nov 1, 2008, 00:00

  • PSY36 EUROPEAN ECONOMIC EVALUATION OF OROS HYDROMORPHONE IN THE MANAGEMENT OF SEVERE CHRONIC CANCER AND NON-CANCER PAIN

    Nov 1, 2008, 00:00

  • PCN39 EXPLORATORY COST EFFECTIVENESS ANALYSIS OF BEVACIZUMAB IN ADDITION TO FOLFOX-4 IN THE ADJUVANT TREATMENT OF STAGE III COLON CANCER- A UK PERSPECTIVE

    Nov 1, 2008, 00:00

  • PMS21 COST-EFFECTIVENESS SIMULATION MODEL OF ABATACEPT VERSUS RITUXIMAB IN RHEUMATOID ARTHRITIS IN FRANCE

    Nov 1, 2008, 00:00

  • PHP4 PATIENT PREFERENCES TOWARD HEALTH SERVICES PROVIDED BY THE GENERAL PRACTIONER

    Nov 1, 2008, 00:00

  • PSS4 RESTOR VERSUS ACRILISA ND-YAG LASER INCIDENCE RATE COMPARISON ONE YEAR AFTER SURGERY

    Nov 1, 2008, 00:00

  • PSY31 ECONOMIC IMPACT OF THE FABRY-ANDERSON DISEASE TREATMENT

    Nov 1, 2008, 00:00

  • PCV112 STATINS USE IN PATIENTS WITH A RECENT ISCHEMIC STROKE- RESULTS FROM THE STROKE ANALYZER DATABASE

    Nov 1, 2008, 00:00

  • QL8 COMPARISON OF CANCER-RELATED FATIGUE USING A ONE- VERSUS FOUR-WEEK RECALL PERIOD

    Nov 1, 2008, 00:00

  • PCN41 ECONOMIC EVALUATION OF TRASTUZUMAB FOR THE ADJUVANT TREATMENT OF HER2 POSITIVE EARLY BREAST CANCER IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PCV80 TISSUE ENGINEERING OF VALVEDVENOUS CONDUITS (VVC) VERSUS CONSERVATIVE THERAPY IN PATIENTS WITH CHRONICVENOUS INSUFFICIENCY (CVI). A DECISION ANALYTIC MODEL USING EXPERT ESTIMATED UTILITIES BASED ON DERIVED DATA FROM ANIMAL STUDIES AS ...

    Nov 1, 2008, 00:00

  • MO2 INCORPORATING CALIBRATED MODEL PARAMETERS INTO SENSITIVITY ANALYSES- DETERMINISTIC AND PROBABILISTIC APPROACHES

    Nov 1, 2008, 00:00

  • PMC18 CONCEPTUALISING DISEASE- BUILDING UNIFYING MODELS TO SUPPORT THE DEVELOPMENT OF PROS AND COST-EFFECTIVENESS ANALYSES. A CASE STUDY IN ALZHEIMER-S DISEASE (AD)

    Nov 1, 2008, 00:00

  • PCV86 COMPARISON OF PERSISTENCE AND ADHERENCE BETWEEN PRASUGREL AND CLOPIDOGREL IN THE TREATMENT OF PATIENTS WITH ACUTE CORONARY SYNDROMES AND PERCUTANEOUS CORONARY INTERVENTIONS

    Nov 1, 2008, 00:00

  • PHC5 A COST-EFFECTIVENESS ANALYSIS OF RHBMP-2 IN SPINE FUSION SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PG110 ONCE DAILY MESALAZINE FOR MAINTAINING REMISSION IS COST-SAVING COMPARED TO TWICE DAILY MESALAZINE- AN ECONOMIC EVALUATION BASED ON THE PODIUM RANDOMISED CONTROLLED TRIAL

    Nov 1, 2008, 00:00

  • PSS39 QUALITY OF LIFE IN MODERATE TO SEVERE PSORIASIS PATIENTS IN SPAIN

    Nov 1, 2008, 00:00

  • PCN90 DEVELOPMENT OF AN EFFECTIVE HOME PALLIATIVE CARE SYSTEM ADOPTING A MULTIDISCIPLINARYTEAM APPROACH-SATISFACTION OF THE PATIENTS FAMILY FOR THE DOMICILIARY PALLIATIVE CARE 'OKAYAMA' MODEL

    Nov 1, 2008, 00:00

  • PMC27 DO LIKERT-TYPE SCALE AND VISUAL ANLOGUE SCALE MEASURE THE SAME QUALITY OF LIFE?

    Nov 1, 2008, 00:00

  • PDB58 PREDICTION MODEL FOR BLOOD GLUCOSE OF TYPE 2 DIABETIC PATIENT

    Nov 1, 2008, 00:00

  • PMC44 THE SIGNIFICANCE OF PATIENT-REPORTED OUTCOMESTO FACILITATE MARKET ACCESS DURING A PRODUCT LIFECYCLE

    Nov 1, 2008, 00:00

  • PG138 RESULTS OF ALEGRIA, A REAL LIFE EVALUATION OF GERD IMPACT OF SYMPTOM ASSESSMENT IN BELGIUM

    Nov 1, 2008, 00:00

  • PIH3 EPIDEMIOLOGICAL SURVEILLANCE OF CONGENITAL MALFORMATIONS IN 52,744 BIRTHS COLOMBIAN BETWEEN APRIL 2001 AND JANUARY 2008

    Nov 1, 2008, 00:00

  • PDB1 THE IMPACT OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN ON LONG-TERM DIABETES-RELATED COMPLICATIONS- A MODELING ANALYSIS IN TYPE 1 DIABETES PATIENTS IN BELGIUM, FRANCE, GERMANY, ITALY AND SPAIN

    Nov 1, 2008, 00:00

  • PMC37 CHALLENGES OF TRANSLATING AND LINGUISTICALLY VALIDATING PRO MEASURES INTO SLAVIC LANGUAGES

    Nov 1, 2008, 00:00

  • PHP7 COMPARING THE ACTUAL HOSPITAL COST OF A PATIENT WITH OESOPHAGEAL CANCERTO NORMATIVE DRG REIMBURSEMENT

    Nov 1, 2008, 00:00

  • PSS58 A SCORING SYSTEM FOR QUALITY OF CARE EVALUATION. A COMMUNITY-BASED STUDY OF CHRONIC LEG ULCERS IN NORTH GERMANY

    Nov 1, 2008, 00:00

  • PMS18 COSTS OF TREATMENT OF RHEUMATOID ARTHRITIS WITH BIOLOGICAL DRUGS

    Nov 1, 2008, 00:00

  • PHP60 COMPARISON OF THE HEALTH ECONOMIC GUIDELINES OF THE CZECH REPUBLIC, HUNGARY, POLAND AND THE SLOVAK REPUBLIC

    Nov 1, 2008, 00:00

  • PMS17 THE ECONOMIC IMPLICATIONS OF ACHIEVING TREATMENT RESPONSE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMH14 THE COST-EFFECTIVENESS OF QUETIAPINE EXTENDED-RELEASE VERSUS OLANZAPINE FOLLOWING GENERIC RISPERIDONE IN PATIENTS WITH FIRST EPISODE SCHIZOPHRENIA

    Nov 1, 2008, 00:00

  • PCV68 IMPACT OF DRUG ELUTING STENTS ON CLINICAL AND ECONOMIC OUTCOMES IN AN UNSELECTED INTERVENTIONAL PRACTICE

    Nov 1, 2008, 00:00

  • PMC3 OVERCOMING THE FINAL HURDLE- COMMUNICATING THE COST EFFECTIVENESS OF A NEW DRUG

    Nov 1, 2008, 00:00

  • AR1 PRODUCTIVITY LOSS AT WORK IN PATIENTS WITH EARLY RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PCN14 A MODELTO DEMONSTRATE THE COMPARATIVE COSTS BETWEEN PANITUMUMAB AND CETUXIMAB FOR THIRD-LINE METASTATIC COLORECTAL CANCER PATIENTS IN ITALY

    Nov 1, 2008, 00:00

  • PCN110 STATISTICAL METHODOLOGY IS CRUCIAL IN PROGNOSTIC FACTOR ANALYSIS OF HEALTH-RELATED QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PRS18 DIFFERENCES IN TREATMENT COSTS AND RESOURCE UTILIZATION AMONG COPD PATIENTS TREATED WITH ALBUTEROL MDI OR LEVALBUTEROL MDI

    Nov 1, 2008, 00:00

  • PMC34 METHODOLOGIES FOR ASSESSING AND DEMONSTRATING DATA SATURATION IN QUALITATIVE INQUIRY SUPPORTING PATIENT-REPORTED OUTCOMES RESEARCH

    Nov 1, 2008, 00:00

  • PCN22 AN ECONOMIC EVALUATION OF CAPECITABINE/CISPLATIN PLUS 5-FU/CISPLATIN REGIMENS IN TREATMENT OF ADVANCED GASTRIC CANCER IN SPAIN

    Nov 1, 2008, 00:00

  • PMS62 DISCONTINUATION RATE OF THE IST AND IIND ANTI-TUMOR NECROSIS FACTORTHERAPIES IN PATIENTS WITH RHEUMATOID ARTHRITIS IN ITALY

    Nov 1, 2008, 00:00

  • PSS46 MELANOTIC TUMOURS- EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PMS30 COSTS AVOIDED BY DIAGNOSING FIBROMYALGIA IN FRENCH PATIENTS

    Nov 1, 2008, 00:00

  • PCN69 PHARMACOECONOMIC ANALYSIS OF THE ADDITION OF RITUXIMAB TO FIRST-LINE CHEMOTHERAPY TREATMENT REGIMENS IN SPANISH PATIENTS WITH ADVANCED FOLLICULAR LYMPHOMA

    Nov 1, 2008, 00:00

  • AR3 TO INVESTIGATE THE BENEFIT OF ANTI-TNF THERAPY ION PHYSICAL AND MENTAL FUNCTIONING VIA THE SHORT FORM-36 QUALITY OF LIFE QUESTIONNAIRE IN PATIENTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • HP2 NEONATAL INTENSIVE CARE UNITS (NICUS) IN GREECE- FACTORS AFFECTING THE LENGTH OF STAY (LOS) OF THE NEONATES AND THE DRIVERS OF COST

    Nov 1, 2008, 00:00

  • PSS36 THE DESCRIPTIVE EPIDEMIOLOGY AND OUTCOME OF HOSPITALISATIONS FOR PSORIASIS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PND30 NATIONAL GUIDELINE FOR MULTIPLE SCLEROSIS TREATMENT IN BRAZILIAN PUBLIC HEALTH- AN ANALYSIS OF TREATMENT PATTERNS AND BUDGET IMPACT

    Nov 1, 2008, 00:00

  • PIH10 THE COST EFFECTIVENESS OF SCHEDULED MAINTENANCE TREATMENT WITH INFLIXIMAB AMONG PAEDIATRIC PATIENTS WITH CROHNS DISEASE IN SCOTLAND

    Nov 1, 2008, 00:00

  • PSS30 COST OF SPECTACLES AFTER CATARACT SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PMS71 A COST-EFFECTIVENESS ASSESSMENT OF ABATACEPT FOR THE TREATMENT OF RHEUMATOID ARTHRITIS IN HUNGARY

    Nov 1, 2008, 00:00

  • PIH21 EFFICACY OF TREATMENT AND PATIENT SATISFACTION IN TREATMENT OF CLIMACTERIC DISORDERS WITH SOY ISOFLAVONES- FRENCH APPROCH

    Nov 1, 2008, 00:00

  • PRS42 SMOKING-CESSATION ACROSS BORDERS- TRANSFERABILITY OF COST-EFFECTIVENESS RESULTS

    Nov 1, 2008, 00:00

  • PMC12 MODELLING THE VALUE FOR MONEY OF CLINICAL PRACTICE CHANGE- A STOCHASTIC APPLICATION IN DIABETES CARE

    Nov 1, 2008, 00:00

  • PHP12 THE BELGIAN REIMBURSEMENT PROCEDURE (BRP)-ARE ADDED THE RAPEUTIC VALUE (ATV) AND ICER AFFECTING THE DRUG REIMBURSEMENT DECISION (DRD)?

    Nov 1, 2008, 00:00

  • PMS4 COST-EFFECTIVENESS ANALYSIS OF LEFLUNOMIDE AS A TREATMENT FOR RHEUMATOID ARTHRITIS IN MEXICO

    Nov 1, 2008, 00:00

  • PCN42 A SENSITIVITY ANALYSIS ON THE COST UTILITY OF BEVACIZUMAB, CAPECITABINE, AND OXALIPLATIN COMPARED WITH FOLFOX FOR THE TREATMENT OF METASTATIC COLORECTAL CANCER (CRC)- A UK PERSPECTIVE

    Nov 1, 2008, 00:00

  • PCASE1 ESTABLISHMENT OF A COST-EFFECTIVENESS (CE) THRESHOLD AT KING HUSSEIN CANCER CENTER- IMATINIB IN CHRONIC MYELOGENOUS LEUKEMIA (CML)

    Nov 1, 2008, 00:00

  • PMS27 COST CONSEQUENCE ANALYSIS OF RITUXIMAB TREATMENT FOR RHEUMATOID ARTHRITIS IN ISRAEL

    Nov 1, 2008, 00:00

  • EE2 STANDARDIZED TYPE 2 DIABETES COMPLICATION COSTS FROM US COMMERCIAL PAYERS TO BE USED IN MODELING THE LONG-TERM ECONOMIC OUTCOMES OF DIABETES COMPLICATIONS

    Nov 1, 2008, 00:00

  • DB3 HEALTH CARE RESOURCE UTILIZATION AND COSTS IN INSULIN-DEPENDENT PATIENTS WITH TYPE 2 DIABETES UNDER REALWORLD CONDITIONS IN GERMANY- LIVE-SPP STUDY

    Nov 1, 2008, 00:00

  • PMS50 FRACTURE INCIDENCE AND CHANGES IN QUALITY OF LIFE AND BACK PAIN INWOMEN WITH OSTEOPOROSIS TREATED WITH TERIPARATIDE- EUROPEAN FORSTEO OBSERVATIONAL STUDY (EFOS) 18 MONTH RESULTS FROM PATIENTS ENROLLED IN FRANCE

    Nov 1, 2008, 00:00

  • PMH15 COST-EFFECTIVENESS OF QUETIAPINE IN COMBINATION WITH LITHIUM/DIVALPROEX IN MAINTENANCE TREATMENT OF BIPOLAR I DISORDER

    Nov 1, 2008, 00:00

  • PIN38 THE ECONOMIC BURDEN OF HCV AND HBV CO-INFECTION- EVIDENCE FROM UNITED STATES MANAGED CARE DATA

    Nov 1, 2008, 00:00

  • PUK1 CLINICAL ATTITUDES ON CHRONIC GRAFT DYSFUNCTION- THE ICEBERG STUDY

    Nov 1, 2008, 00:00

  • PDB68 LONG-TERM COST-EFFECTIVENESS OF INSULIN DETEMIR COMPARED TO NEUTRAL PROTAMINE HAGEDORN INSULIN IN PATIENTS WITH TYPE 1 DIABETES USING A BASAL-BOLUS REGIMEN IN SWEDEN

    Nov 1, 2008, 00:00

  • PCV61 INFLUENCE THE CO-MORBIDITY AND DIRECT COSTS OF STROKETO POPULATION SETTING AND IN CLINICAL PRACTICE

    Nov 1, 2008, 00:00

  • PSS45 A TOPICAL DERMATITIS- EVALUATION OF SELF-PERCEIVED STRESS AND QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PHP43 GREEK HOSPITALS SUPPLY CHAIN MANAGEMENT

    Nov 1, 2008, 00:00

  • PMH38 CAN PATIENTS WITH SCHIZOPHRENIA COMPLETE A CONJOINT ANALYSIS? EVIDENCE FROM GERMANY

    Nov 1, 2008, 00:00

  • PDB24 A COST-EFFECTIVENESS ANALYSIS OF IRBESARTAN IN THE TREATMENT OF HYPERTENSIVE PATIENTS WITH DIABETIC RENAL DISEASE

    Nov 1, 2008, 00:00

  • PMS59 RESTORATIVE EFFECT OF SLEEP- VALIDATION OF THE SQA (SLEEP QUALITY ASSESSMENT)

    Nov 1, 2008, 00:00

  • CASE1 IMPLEMENTATION OF TRANSPARENT PROCESS OF DRUG REIMBURSEMENT DECISIONS IN POLAND

    Nov 1, 2008, 00:00

  • PMS19 COST-EFFECTIVENESS OF USING ETANERCEPT AS FIRST LINE IN SEVERE AND HIGHLY ACTIVE RHEUMATOID ARTHRITIS (RA)

    Nov 1, 2008, 00:00

  • PUK13 EXPANDED CRITERIA DONORS IN RENAL TRANSPLANTATION- RESULTS OF ECONOMIC EVALUATION

    Nov 1, 2008, 00:00

  • PIH7 ECONOMIC ANALYSIS OF TREATMENT WITH IUI-COH VERSUS 6 MONTHS DELAY OF TREATMENT IN COUPLES WITH UNEXPLAINED SUBFERTILITY

    Nov 1, 2008, 00:00

  • PMC25 IS THE EQ-5D QUESTIONNAIRE A PREDICTOR OF MORTALITY AND HOSPITALIZATION IN A GENERIC ELDERLY POPULATION?

    Nov 1, 2008, 00:00

  • PSS43 A TOPIC DERMATITIS AND THERMAL THERAPY- EVALUATION OF MEDICAL SERVICE

    Nov 1, 2008, 00:00

  • PCN67 COST UTILITY ANALYSIS OF ALEMTUZUMAB COMPARED TO CHLORAMBUCIL IN UNTREATED PATIENTS WITH HIGH-RISK (17P-) CHRONIC LYMPHOCYTIC LEUKEMIA IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PIH5 INCIDENCE OF MAJOR MALFORMATIONS IN INFANTS FOLLOWING ANTIDEPRESSANT EXPOSURE IN PREGNANCY- RESULTS OF A LARGE PROSPECTIVE COHORT STUDY

    Nov 1, 2008, 00:00

  • PIN33 COST-MINIMIZATION ANALYSIS OF DAPTOMYCIN FOR MRSA SKIN AND SOFT TISSUES INFECTIONS IN BRAZILIAN PRIVATE SECTOR

    Nov 1, 2008, 00:00

  • PMS46 DEVELOPMENT OF A SPECIFIC TOOL TO EVALUATE WOMENS ADHERENCE TO OSTEOPOROSIS TREATMENT

    Nov 1, 2008, 00:00

  • PSY57 USE OF AN ADMINISTRATIVE DATABASE TO ESTIMATE THE NUMBER OF HOSPITAL ADMISSIONS FOR IMMUNE THROMBOCYTOPENIC PURPURA AND ITS ECONOMIC BURDEN IN FRANCE

    Nov 1, 2008, 00:00

  • PMH43 THE SPANISH VERSION OF THE TOOL QUESTIONNAIRE- A USEFUL MEASURE FOR EVALUATING THE HRQOL AND UTILITIES FROM SCHIZOPHRENIC AND BIPOLAR PATIENTS

    Nov 1, 2008, 00:00

  • PCV63 CO-MORBIDITY AND DIRECT COSTS ACCORDING THE CARDIOVASCULAR RISK LEVEL IN A SPANISH POPULATION SETTING

    Nov 1, 2008, 00:00

  • PRS32 SYMPTOMS AND IMPACT OF SYMPTOMS AS REPORTED BY ASTHMA PATIENTS

    Nov 1, 2008, 00:00

  • PCV71 COST-UTILITY ANALYSIS IN PATIENTS WITH DRUG REFRACTORY CONCOMITANT A TRIAL FIBRILLATION IN SPAIN

    Nov 1, 2008, 00:00

  • AR2 A COST EFFECTIVENESS ANALYSIS OF INFLIXIMAB TREATMENT IN PATIENTS WITH RHEUMATOID ARTHRITIS (RA) IN SWEDEN, BASED ON DATA FROM THE STURE REGISTRY

    Nov 1, 2008, 00:00

  • PMS15 LEFLUNOMIDE IN THE TREATMENT OF RHEUMATOID ARTHRITIS IN POLAND-A BUDGET IMPACT ANALYSIS

    Nov 1, 2008, 00:00

  • PCN108 DEVELOPMENT OF AN INTERACTIVE MODEL OF FINANCIAL ACCESS TO CANCERTHERAPY

    Nov 1, 2008, 00:00

  • PDB44 TREATMENT COMPLIANCE AND ILLNESS KNOWLEDGE IN DIABETIC PATIENTS ATTENDED IN SPANISH PRIMARY CARE CENTRES

    Nov 1, 2008, 00:00

  • PCV79 ECONOMIC EVALUATION OF IRBESARTAN IN GREECE

    Nov 1, 2008, 00:00

  • PCN25 COST-EFFECTIVENESS ANALYSIS OF TRASTUZUMAB THERAPY IN EARLY HER-2 POSITIVE BREAST CANCER PATIENTS- THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM CASE

    Nov 1, 2008, 00:00

  • PHP19 REGIONAL MARKET ACCESS IN EQUALITIES FOR NEW ONCOLOGY DRUGS IN SPAIN

    Nov 1, 2008, 00:00

  • PCV48 ENHANCING SYNCOPE DIAGNOSTICS- COST-EFFECTIVENESS ANALYSIS OF AN IMPLANTABLE LOOP RECORDER STRATEGY VERSUS THE STANDARD OF CARE

    Nov 1, 2008, 00:00

  • PSY19 MEDICAL AND COST EFFECTIVENESS OF BARIATRIC SURGERY IN OBESITY. RESULTS OF AN HTA COMMISIONED BY THE GERMAN AGENY FOR HEALTHTECHNOLOGY ASSESSMENT

    Nov 1, 2008, 00:00

  • PSS32 COST-EFFECTIVENESS ANALYSIS OF THE FIXED COMBINATION GLAUCOMA MEDICATIONS BRIMONIDINE/TIMOLOL AND DORZOLAMIDE/TIMOLOL IN 10 EUROPEAN COUNTRIES

    Nov 1, 2008, 00:00

  • PCV25 BUDGET IMPACT ANALYSIS OF THROMBOLYSIS FOR STROKE- A DISCRETE EVENT SIMULATION MODEL

    Nov 1, 2008, 00:00

  • PHP36 PERFORMANCE OF YOUR 5-STAR HOSPITALS

    Nov 1, 2008, 00:00

  • PSY35 COST-EFFECTIVENESS ANALYSIS OF THE EPOETIN TREATMENT IN PATIENTS WITH ANEMIA INDUCED BY CHEMOTHERAPY, EPICOST STUDY PRELIMINARY RESULTS (ONVIDA GROUP)

    Nov 1, 2008, 00:00

  • PCN13 BUDGET IMPACT ANALYSIS OF THE CONTINUATION OF DOCETAXEL REIMBURSEMENT IN THE NEOADJUVANT THERAPY OF LOCALLY ADVANCED BREAST CANCER AND PALLIATIVE THERAPY OF METASTATIC BREAST CANCER IN POLAND

    Nov 1, 2008, 00:00

  • PCN63 METASTATIC COLORECTAL CANCER- MEDICAL COSTS OF FIRST LINE INFUSIONAL 5-FLUOROURACIL OR ORAL CAPECITABINE IN ITALIAN PATIENTS

    Nov 1, 2008, 00:00

  • PMC36 AN INVESTIGATION OF FACTORIAL STRUCTURE OF SF-36V2 IN THE US GENERAL POPULATION-THE APPLICATION OF CONFIRMATORY FACTOR ANALYSIS THROUGH STRUCTURAL EQUATION MODELLING

    Nov 1, 2008, 00:00

  • PMC38 INFLUENCE OF DEMOGRAPHIC AND CULTURAL PREDICTORS ON EQ-5D VALUE SET IN THE POLISH POPULATION

    Nov 1, 2008, 00:00

  • PCN15 A COST-EFFECTIVENESS ANALYSIS OF IXABEPILONE FOR BREAST CANCER AT ATERTIARY CANCER CENTER

    Nov 1, 2008, 00:00

  • PCN93 THE IMPACT OF A COST ATTRIBUTE ON PREFERENCES

    Nov 1, 2008, 00:00

  • PSS55 USTEKINUMAB REDUCESWORK LIMITATIONS, INCREASES WORK PRODUCTIVITY AND DECREASESWORKDAYS MISSED DUETO PSORIASIS IN PATIENTS WITH MODERATE TO SEVERE PSORIASIS

    Nov 1, 2008, 00:00

  • PSY47 PATIENT-REPORTED OUTCOMES (PRO) IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRACTICE CONDITIONS

    Nov 1, 2008, 00:00

  • CN4 YEARS OF POTENTIAL LIFE LOST AND PRODUCTIVITY COSTS DUETO CANCER MORTALITY AND FOR SPECIFIC CANCER SITES WHERE HPV MAY BE A RISK FACTOR FOR CARCINOGENESIS-UNITED STATES, 2003

    Nov 1, 2008, 00:00

  • PSY27 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO NECK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL PRA ...

    Nov 1, 2008, 00:00

  • PDB34 MONITORING OF TREATMENT COSTS AFTER REIMBURSEMENT DECISION- SOMATOSTATIN ANALOGUES FOR ACROMEGALY

    Nov 1, 2008, 00:00

  • PCV4 COMPARISON OF THE CLINICAL AND ECONOMIC EFFECTIVENESS OF SIROLIMUS-ELUTING VERSUS BARE-METAL STENTS IN A SUBGROUP OF PATIENTS WITH AND WITHOUT DIABETES

    Nov 1, 2008, 00:00

  • PMC32 METHODS FOR ADDRESSING USE OF PRO INSTRUMENTS IN THE SAME LANGUAGE FOR DIFFERENT COUNTRIES- BEST PRACTICE GUIDELINES FOR DECISION-MAKING AND TRANSLATION OR ADAPTATION

    Nov 1, 2008, 00:00

  • PRS11 COST-EFFECTIVENESS OF INCREASING MAINTENANCE DOSES WITH BUDESONIDE/FORMOTEROL MAINTENANCE RELIEVER THERAPY

    Nov 1, 2008, 00:00

  • PDB2 IMPROVED GLYCAEMIC CONTROL BY SWITCHING FROM INSULIN NPHTO INSULIN GLARGINE- A RETROSPECTIVE OBSERVATIONAL STUDY

    Nov 1, 2008, 00:00

  • PIN29 EFFECTIVENESS AND COST-EFFECTIVENESS OF HEPATITIS C SCREENING-A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • CN5 EXPLORATORY ECONOMIC EVALUATION OF ADJUVANT TREATMENT OF NON-SMALL-CELL LUNG CANCER (NSCLC) WITH BEVACIZUMAB IN ADDITION TO A CISPLATIN-BASED TREATMENT REGIMEN IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PMS57 VALIDITY AND RESPONSIVENESS OF THE WORK PRODUCTIVITY SURVEY- A NOVEL DISEASE-SPECIFIC INSTRUMENT ASSESSINGWORK PRODUCTIVITY WITHIN AND OUTSIDE THE HOME IN SUBJECTS WITH RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PMC4 FEASIBILITY OF CONDUCTING BUDGET IMPACT ANALYSIS IN THE SOCIAL SECURITY INSTITUTION OF TURKEY

    Nov 1, 2008, 00:00

  • PIN23 COST-EFFECTIVENESS ANALYSIS OF 7-VALENT PNEUMOCOCCAL CONJUGATE VACCINE IN TAIWAN- TRANSMISSION DYNAMIC MODEL-BASED EVALUATIONS

    Nov 1, 2008, 00:00

  • PMH23 THE ECONOMIC EFFECTS OF FASTER TITRATION AND LOWER RELAPSE RATE OF QUETIAPINE XR COMPARED TO QUETIAPINE IR-THE ECONOMICVALUE OF A NEW DRUG FORMULATION

    Nov 1, 2008, 00:00

  • PUK11 A COST-UTILITY ANALYSIS OF SOLIFENACIN 5 MG AND SOLIFENACIN 10 MGVERSUS TOLTERODINE ER 4 MG IN THE PHARMACOLOGICAL TREATMENT OF PATIENTS WITH OVERACTIVE BLADDER (OAB)

    Nov 1, 2008, 00:00

  • PMS65 GOLIMUMAB, A HUMAN ANTI-TNF-ALPHA MONOCLONAL ANTIBODY, SIGNIFICANTLY IMPROVES SELF-REPORTED PRODUCTIVITY IN PATIENTS WITH RHEUMATOID ARTHRITIS- RESULTS FROMTHREE PHASE 3 STUDIES

    Nov 1, 2008, 00:00

  • PRS9 COST-EFFECTIVENESS MODEL OF MOXIFLOXACIN IN ACUTE EXACERBATIONS OF CHRONIC BRONCHITIS (AECB) IN GERMANY INCLUDING THE EFFECTS OF RESISTANCE

    Nov 1, 2008, 00:00

  • PCN94 COST-EFFECTIVENESS AND PREFERENCE FOR FOLLOW-UP SCENARIOS FOLLOWING BREAST CANCER

    Nov 1, 2008, 00:00

  • PSY9 BUDGET IMPACT OF THE USE OF OROS HYDROMORPHONE ONCE DAILY IN SEVERE CHRONIC PAIN PATIENTS IN THE GERMAN HEALTH CARE SYSTEM

    Nov 1, 2008, 00:00

  • HT3 A COMPARISON OF REASONS FOR RECOMMENDATION AND REJECTION IN FOUR HEALTHTECHNOLOGY APPRAISAL SYSTEMS- NICE, SMC, CADTH AND PBAC

    Nov 1, 2008, 00:00

  • PHP48 THE EFFECTS OF NICE HTAS ON PRESCRIPTION VOLUME, AVERAGE RETAIL PRICE AND AVERAGE OUT-OF-POCKET COSTS OF DRUGS DEEMED MEDICALLY NECESSARY FOR MEDICARE PART D REIMBURSEMENT IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PHP24 USE OF THE AMCP FORMAT IN THE U.S.-A NATIONAL SURVEY OF HEALTH PLANS

    Nov 1, 2008, 00:00

  • PDB32 MEDICAL COSTS ATTRIBUTABLE TO OBESITY IN PATIENTS WITH DIABETES MELLITUS AMONG U.S.ADULTS

    Nov 1, 2008, 00:00

  • PDB41 COST-EFFECTIVENESS OF SOMATROPIN (NORDITROPIN) FOR THE TREATMENT OF GROWTH HORMONE DEFICIENT (GHD) CHILDREN IN A UK SETTING

    Nov 1, 2008, 00:00

  • PCV111 COST-ANALYSIS OF DYSLIPOPROTEINAEMIA TREATMENTS WITHIN THE SLOVAK REPUBLIC

    Nov 1, 2008, 00:00

  • PIN50 A REVIEW OF THE FACTORS AFFECTING PUBLIC FUNDING OF VACCINES

    Nov 1, 2008, 00:00

  • PCV60 TWO-YEAR HOSPITALIZATION RATES AND ASSOCIATED COSTS IN PATIENTS FROM GERMANY WITH PERIPHERAL ARTERIAL DISEASE- RESULTS FROMTHE REDUCTION OF AT HEROTHROMBOSIS FOR CONTINUED HEALTH (REACH) REGISTRY

    Nov 1, 2008, 00:00

  • PCN2 EFFICACY OF LEUPRORELIN 3.75MG COMPARED TO 7.5MG IN THE TREATMENT OF PROSTATE CANCER- SYSTEMATIC REVIEW AND META-ANALYSIS

    Nov 1, 2008, 00:00

  • PCN97 TREATMENT OF PATIENTS WITH METASTATIC BREAST CANCER (MBC) IN THE UKWHO PROGRESS ON TRASTUZUMAB AND HAVE PREVIOUSLY RECEIVED AN ANTHRACYCLINE AND ATAXANE- A NEED FOR EVIDENCE BASED THERAPIES?

    Nov 1, 2008, 00:00

  • PDB12 ASSOCIATION BETWEEN HYPOGLYCEMIA EPISODES AND CHANGES IN THE SULPHONYLUREA TREATMENT PATTERN IN TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS. RECAP-DM SPANISH COHORT STUDY

    Nov 1, 2008, 00:00

  • PCV110 THE POTENTIAL ECONOMIC IMPACTS OF RECONFIGURING TIA CARE IN THE UK

    Nov 1, 2008, 00:00

  • PMS51 MAJOR DETERMINANTS OF EUROQOL (EQ-5D) IN PATIENTS WITH RHEUMATOID ARTHRITIS BASED ON A LARGE JAPANESE COHORT IORRA

    Nov 1, 2008, 00:00

  • PMH62 ECONOMIC OUTCOMES OF CO-TREATMENT OF INSOMNIA AND MAJOR DEPRESSIVE DISORDER (MDD) WITH ESZOPICLONE AND FLUOXETINE VERSUS FLUOXETINE TREATMENT ALONE

    Nov 1, 2008, 00:00

  • PCN56 HOSPITAL BURDEN OF DISEASE ASSOCIATED WITH METASTATIC BONE DISEASE (MBD) AND SKELETAL-RELATED EVENTS (SRES) IN PATIENTS WITH BREAST CANCER (BC) AND PROSTATE CANCER (PC) IN SPAIN

    Nov 1, 2008, 00:00

  • PMH49 INTERNATIONAL INVESTIGATION INTO DEPRESSION BASED ON THE STRUCTURED INTERVIEW GUIDE FOR THE HAMILTON DEPRESSION RATING SCALE (SIGH-D) AND THE CLINICIAN RATED INVENTORY OF DEPRESSIVE SYMPTOMATOLOGY (IDS-C)

    Nov 1, 2008, 00:00

  • PMH60 DETERMINANTS OF PRESCRIPTION IN PRIMARY CARE- PROFILE OF PATIENTS PRESCRIBED NEWER ANTIDEPRESSANTS IN THE UNITED KINGDOM

    Nov 1, 2008, 00:00

  • PDB56 IDENTIFYING FACTORSTHAT AFFECT PATIENTS WILLINGNESS TO PAY FOR INHALED INSULIN

    Nov 1, 2008, 00:00

  • PMH57 SECOND GENERATION ANTIPSYCHOTICS AND HOSPITALIZATION IN BIPOLAR DISORDER- A CLAIMS DATA ANALYSIS

    Nov 1, 2008, 00:00

  • PG17 AN ECONOMIC EVALUATION OF THE TWO LEADING ALGINTE THERAPIES IN THE UK- RESULTS FROM A LARGE LONGITUDINAL DATABASE

    Nov 1, 2008, 00:00

  • PCN49 COST-MINIMISATION ANALYSIS OF MAINTENANCE THERAPIES FOR PROSTATE CANCER IN THE UK

    Nov 1, 2008, 00:00

  • PSS17 SENSITIVE SKINS IN BELGIUM- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PMS31 OSTEOARTHRITIS AND JOB ABSENTEEISM COSTS- EVIDENCE FROM U.S. NATIONAL SURVEY DATA

    Nov 1, 2008, 00:00

  • PCN9 COST OF MANAGEMENTVERSUS REIMBURSEMENT COST OF THE MANAGEMENT OF PATIENTS WITH SOLIDTUMORS PRESENTING A FEBRILE NEUTROPENIA

    Nov 1, 2008, 00:00

  • PHP58 EVALUATING THE PERFORMANCE OF AN INNOVATIVE PUBLIC HEALTH INSURANCE- THE CASE OF A DECENTRALIZED PROVINCE IN ARGENTINA

    Nov 1, 2008, 00:00

  • PHC12 COMPARING TIME AND SUPPLIES USAGE ASSOCIATED WITH A NEW SKIN CLOSURE DEVICE VS. STANDARD OF CARE WOUND CLOSURE FOR ABDOMINOPLASTY SURGERY IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PND8 COST-EFFECTIVENESS ANALYSIS OF REBIF IN FIRST-LINE RELAPSING REMITTING MULTIPLE SCLEROSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PSY28 HEALTH CARE AND NON-HEALTH CARE RESOURCES UTILIZATION AND RELATED COSTS IN SUBJECTS WITH REFRACTORY PAIN ASSOCIATED TO LOW BACK PAIN- A POST-HOC ANALYSIS OF THE EFFECT OF PREGABALIN IN A 12-WEEK PROSPECTIVE STUDY UNDER ROUTINE MEDICAL ...

    Nov 1, 2008, 00:00

  • PMH37 SWITCHING OF ANTIPSYCHOTICS FROM THE PATIENTS POINT OF VIEW- RESULTS OF A QUANTITATIVE PATIENT SURVEY

    Nov 1, 2008, 00:00

  • PDB55 PSYCHOMETRIC STRENGTH OF CURRENT TREATMENT SATISFACTION QUESTIONNAIRES IN NON-INSULIN TREATED TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PCN98 RACIAL DIFFERENCES IN MEDICATION-RELATED HEALTH CARE COSTS AND SERVICE UTILIZATION IN HORMONE RECEPTOR POSITIVE PRIMARY BREAST CANCER PATIENTS

    Nov 1, 2008, 00:00

  • CN2 ESTIMATING TARGET POPULATION SIZE FOR BUDGET IMPACT- AN EPIDEMIOLOGICAL MODEL OF BREAST CANCER AND PROGRESSION TO BONE METASTASIS IN THE UK.

    Nov 1, 2008, 00:00

  • PIN17 COST-EFFECTIVENESS OF MASS VACCINATION FOR VARICELLA IN FRANCE WITH MMRV VERSUS MMR

    Nov 1, 2008, 00:00

  • PCV56 AN ECONOMIC ANALYSIS OF INDUCTION OF LABOR AND EXPECTANT MANAGEMENT INWOMEN WITH PREGNANCYINDUCED HYPERTENSION OR PREECLAMPSIA AT TERM (HYPITAT TRIAL)

    Nov 1, 2008, 00:00

  • PMH12 BUDGET IMPACT OF GENERIC ANTIPSYCHOTIC SUBSTITUTION-A DATABASE ANALYSIS IN GERMANY

    Nov 1, 2008, 00:00

  • PND15 THE INDIRECT COST BURDEN OF EPILEPSY IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • QL4 PREDICTING EQ-5D, SF-6D AND 15D UTILITIES FROM EORTC QLQ-C30 DATA

    Nov 1, 2008, 00:00

  • PDB46 DIABETES RELATED QUALITY OF LIFE IN PORTUGUESE PATIENTS

    Nov 1, 2008, 00:00

  • PHP32 COST-BENEFIT ANALYSIS OF PUBLIC HOSPITAL DEVELOPMENT

    Nov 1, 2008, 00:00

  • PCV55 PHARMACOECONOMIC EVALUATION OF TREATMENT WITH PROCORALAN PREPARATION COMPARED TO INVASIVE TREATMENT

    Nov 1, 2008, 00:00

  • PSS44 A TOPIC DERMATITIS PSORIASIS- CROSS-EVALUATION OF QUALITY OF LIFE

    Nov 1, 2008, 00:00

  • PMC43 USE OF AND COMPLIANCE WITH ELECTRONIC PATIENT REPORTED OUTCOMES WITHIN CLINICAL DRUGTRIALS

    Nov 1, 2008, 00:00

  • PMH5 COMPARISON OF RISK OF UPPER GASTROINTESTINAL HEMORRHAGE AMONG SSRI-USERS WITHIN U.S. MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PCV104 EVALUATION OF THE PRESCRIPTION PATTERNS OF STATINS THROUGH APPROPRIATE INDICATORS IN TWO ITALIAN LOCAL HEALTH UNITS IN 2004-2006

    Nov 1, 2008, 00:00

  • PMH46 PATIENT PREFERENCES IN ADHD-DISCRETE CHOICE EXPERIMENT

    Nov 1, 2008, 00:00

  • PMS48 PATIENT EXPECTATIONS IN HEALTH RELATED QUALITY OF LIFE OUTCOMES IN TOTAL JOINT REPLACEMENT

    Nov 1, 2008, 00:00

  • PSY11 EONOMIC EVALUATION OF ETANERCEPT COMPARED TO NO SYSTEMIC THERAPY IN THE MANAGEMENT OF LESS SEVERE CHRONIC PLAQUE PSORIASIS IN THE UK

    Nov 1, 2008, 00:00

  • PSY10 ESTIMATION OF THE COSTS FOR A HEREDITARY HEMOCHROMATOSIS GENETIC SCREENING PROGRAMME PER 100.000 INDIVIDUALS UNDER 30YEARS OF AGE IN SPAIN

    Nov 1, 2008, 00:00

  • PIH11 COST OF INSOMNIA IN PATIENTS OVER 54 YEARS IN SWEDEN

    Nov 1, 2008, 00:00

  • QL1 AGGREGATION OF DATA FROM MULTIPLE LANGUAGES AND CULTURES- REPORT FROM THE ISPOR TASK FORCE ON TRANSLATION AND LINGUISTIC VALIDATION

    Nov 1, 2008, 00:00

  • PND3 ANTI-EPILEPTIC MEDICATION DRUG FORMULATION CHANGES AND THEIR RELATIONSHIP TO OUTCOMES (AMBULANCE, EMERGENCY DEPARTMENT AND INPATIENT EVENTS)

    Nov 1, 2008, 00:00

  • PMS8 PREVALENCE OF FIBROMYALGIA IN ITALY

    Nov 1, 2008, 00:00

  • PSY56 HEALTH-RELATED QUALITY OF LIFE AND PRODUCTIVITY AMONG HEMOPHILIA PATIENTS WITH INHIBITORS

    Nov 1, 2008, 00:00

  • PDB4 GLYCEMIC CONTROL OF TYP-2 DIABETES IN MAKKAH SECURITY FORCES HEALTH CARE CENTER (MSFHCC), SAUDI ARABIA- A DISCRIPTIVE PILOT STUDY

    Nov 1, 2008, 00:00

  • PSY37 HEALTH AND ECONOMIC CONSEQUENCES OF PATHOGEN TRANSMISSION RISK IN THE TREATMENT OF HAEMOPHILIA A WITH FACTOR VIII

    Nov 1, 2008, 00:00

  • PSY54 UNDERSTANDING PATIENT PERCEPTION OF THE BIOENTERICS INTRAGASTRIC SYSTEM FOR WEIGHT REDUCTION

    Nov 1, 2008, 00:00

  • PSS51 SCORING AND PSYCHOMETRIC VALIDATION OF THE FREEDOM FROM GLASSES VALUE SCALE (FGVS)

    Nov 1, 2008, 00:00

  • PDB64 EFFECTS OF DOSING REGIMEN ON MEDICATION USE BEHAVIOR IN MEDICAID ENROLLED TYPE 2 DIABETES MELLITUS PATIENTS

    Nov 1, 2008, 00:00

  • CN7 MODELING THE COST-EFFECTIVENESS OF A NEW AND EXPENSIVE TREATMENT MODALITY IN LUNG CANCER- THE CASE OF PARTICLE THERAPY

    Nov 1, 2008, 00:00

  • PCN35 ECONOMIC EVALUATION OF CYCLOPHOSPHAMIDE, DOXORUBICIN, VINCRISTINE AND PREDNISONE (CHOP) CHEMOTHERAPY REGIME WITH OR WITHOUT RITUXIMAB (R) IN THE 2ND LINE TREATMENT OF FOLLICULAR NON-HODGIN LYMPHOMA

    Nov 1, 2008, 00:00

  • PSY53 SATISFACTION WITH IRON CHELATION THERAPY IS ASSOCIATED WITH IMPROVED QUALITY OF LIFE IN PATIENTS WITH IRON OVERLOAD

    Nov 1, 2008, 00:00

  • PCN58 MEDICAL RESOURCE CONSUMPTION RELATED TO THE TREATMENT OF IRINOTECAN REFRACTORY ADVANCED COLORECTAL CANCER PATIENTS

    Nov 1, 2008, 00:00

  • PMC52 LINGUISTIC VALIDATION OF THE FRENCH FOR CANADA WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE, GENERAL HEALTHVERSION (WPAI-GH)

    Nov 1, 2008, 00:00

  • PHP51 OTHER HEALTHTECHNOLOGY ASSESSMENT GROUPS OPERATING IN ENGLAND; ITS NOT JUST NICETHAT NEEDS TO BE TAKEN INTO CONSIDERATION

    Nov 1, 2008, 00:00

  • PUK14 A HEALTH ECONOMIC EVALUATION OF THE USE OF ERYTHROPOIESIS-STIMULATING AGENTS (ESA) IN PATIENTS WITH RENAL FAILURE TREATED WITH HAEMODIALYSIS

    Nov 1, 2008, 00:00

  • PMH34 WORKPLACE BURDEN OF MILD, MODERATE, AND SEVERE DEPRESSION IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PCV84 HEALTH CARE RESOURCES AND QUALITY OF LIFE IN ACUTE CORONARY SYNDROME PATIENTS IN 2007- FRENCH BASELINE RESULTS FROM THE ANTIPLATELET TREATMENT OBSERVATIONAL STUDY (APTOR)

    Nov 1, 2008, 00:00

  • PCN65 A PHARMACOECONOMIC MODEL FOR THE MANAGEMENT OF CANCER PAIN- OPIOID MARKET WITH OR WITHOUT OROS HYDROMORPHINE IN TURKEY

    Nov 1, 2008, 00:00

  • PHP14 THE COMPETITIVE ACQUISITION PROGRAM (CAP)- WHERE IS IT AFTER TWO YEARS?

    Nov 1, 2008, 00:00

  • PCV117 COMPARATIVE ANALYSIS OF HEALTHTECHNOLOGY ASSESSMENTS (HTA) OF DRUG ELUTING STENTS (DES)

    Nov 1, 2008, 00:00

  • PSS3 VISION WITH RESTOR, ARRAY SA40 AND A MONOFOCAL INTRA-OCULAR LENS (IOL) AFTER CATARACT SURGERY

    Nov 1, 2008, 00:00

  • PSS19 SENSITIVE SKINS IN GREECE- AN EPIDEMIOLOGICAL APPROACH

    Nov 1, 2008, 00:00

  • PCV38 EXTENDED PROPHYLAXIS OF VENOUSTHROMBOEMBOLISM (VTE) IN PATIENTS UNDERGOING MAJOR ORTHOPAEDIC SURGERY IN ITALY- A PHARMACOECONOMIC STUDY

    Nov 1, 2008, 00:00

  • PRS19 RATES OF DISCONTINUATION AMONG COMMONLY PRESCRIBED MEDICATIONS IN THE US

    Nov 1, 2008, 00:00

  • PHP52 EVALUATION OF CURRENT ASSESSMENTS OF WORLDWIDE AGENCIES FOR HEALTHTECHNOLGY ASSESSMENT

    Nov 1, 2008, 00:00

  • IN3 PHARMACOECONOMIC ANALYSIS OF ITRACONAZOLE ORAL SOLUTION IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKEY

    Nov 1, 2008, 00:00

  • PSS48 HOSPITAL DERMATOLOGY CONSULTATION TYPES- A FRENCH ASSESSMENT

    Nov 1, 2008, 00:00

  • PCV72 COST/UTILITY ANALYSIS (CUA) OF VALSARTAN FOR THE TREATMENT OF CONGESTIVE HEART FAILURE (CHF) IN ITALY BASED ON THE VAL-HEFT TRIAL

    Nov 1, 2008, 00:00

  • PND16 INDIRECT COSTS OF ALZHEIMERS DISEASE IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PG133 A POPULATION-BASED SURVEY TO ASSESS IMPACT OF TROUBLESOME SYMPTOMS IN GASTROESOPHAGEAL REFLUX DISEASE ON WORK PRODUCTIVITY

    Nov 1, 2008, 00:00

  • PND13 ALZHEIMERS DISEASE PRESCRIPTION MEDICATION COSTS- 2004-2005

    Nov 1, 2008, 00:00

  • PUK15 ASSESSMENT OF THE BENEFITS OF TIME SAVINGS ACHIEVED BY ONCE MONTHLY INJECTION OF ERYTHROPOIETIN STIMULATING AGENTS (ESA) ON ANAEMIA MANAGEMENT IN HAEMODIALYSIS CENTRES

    Nov 1, 2008, 00:00

  • DB1 ESTIMATING THE LONG-TERM CLINICAL AND ECONOMIC BENEFITS OF INSULIN LISPRO IN TYPE 1 DIABETES IN THE UNITED KINGDOM- A COST-EFFECTIVENESS ANALYSIS BASED ON THE RESULTS OF A RECENT META-ANALYSIS

    Nov 1, 2008, 00:00

  • PMH22 IMPACT ON SCHIZOPHRENIA INPATIENT RESOURCE USE FOLLOWING SWITCHTO LONG-ACTING RISPERIDONE IN FINLAND

    Nov 1, 2008, 00:00

  • PDB21 COST-EFFECTIVENESS OF INSULIN GLARGINE PLUS ORAL ANTIDIABETIC DRUGS (OADS) COMPARED TO PREMIXED INSULIN FOR TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE CANADIAN PAYER SETTING

    Nov 1, 2008, 00:00

  • QL3 ACCESS TO HEALTH-RELATED QUALITY OF LIFE (HRQL) INSTRUMENTS AND THEIR TRANSLATIONS IN THE LIGHT OF EMEA RECOMMENDATIONS

    Nov 1, 2008, 00:00

  • PCN57 PALLIATIVE CARE FOR CANCER PATIENTS IN BRAZIL- A COST-OF-ILLNESS STUDY

    Nov 1, 2008, 00:00

  • PDB26 COST-EFFECTIVENESS OF ROSIGLITAZONE COMBINATION THERAPY FOR THE TREATMENT OF TYPE 2 DIABETES IN THE CZECH REPUBLIC

    Nov 1, 2008, 00:00

  • PDB14 LARGE IMPACT OF ANTIDIABETIC DRUGTREATMENT AND HOSPITALIZATIONS ON ECONOMIC BURDEN OF DIABETES MELLITUS IN THE NETHERLANDS DURING 2000 TO 2004

    Nov 1, 2008, 00:00

  • PMS52 THE QUALITY OF LIFE OF SUFFERERS OF OSTEOARTHRITIS- THE IMPACT OF TREATMENT

    Nov 1, 2008, 00:00

  • PCN53 COST IMPACT OF CAPECITABINE THERAPY INTRODUCTION IN BREAST CANCER PATIENTS

    Nov 1, 2008, 00:00

  • EE8 COST EFFECTIVENESS OF CAPECITABINE IN COMBINATION WITH OXALIPLATIN (XELOX) COMPARED TO FOLFOX (5-FU, LV, OXALIPLATIN) FOR THE TREATMENT OF METASTATIC CARCINOMA OF THE COLON OR RECTUM (CRC) FROM A UK NATIONAL HEALTH SERVICE (NHS) PERSPEC ...

    Nov 1, 2008, 00:00

  • PMC42 PATIENT AND POPULATION HEALTH-STATE VALUES ARE COMPARABLEWHEN DERIVED BY ELEMENTARY MEASUREMENT METHODS

    Nov 1, 2008, 00:00

  • PMC11 IMPROVING PROBABILISTIC SENSITIVITY ANALYSIS (PSA) IN THE TREATMENT OF UNCERTAINTY COSTS USING MCMC

    Nov 1, 2008, 00:00

  • PRS29 SOCIOECONOMIC ANALYSIS OF SMOKERS PROFILE WHO INTENDS TO QUIT

    Nov 1, 2008, 00:00

  • PMC8 DESIGN AND REPORTING TRENDS IN PIGGY-BACK ECONOMIC TRIALS

    Nov 1, 2008, 00:00

  • PND2 HUNTINGTONS DISEASE- WHERE HAVEWE BEEN?

    Nov 1, 2008, 00:00

  • PMS55 EURO QOL (EQ-5D) BASED QOL (QUALITY OF LIFE) IN 5,023 JAPANESE PATIENTS WITH RHEUMATOID ARTHRITIS (RA) PATIENTS IN AN OBSERVATIONAL COHORT IORRA

    Nov 1, 2008, 00:00

  • PMS60 QUALITATIVE STEPS FOR THE DEVELOPMENT OF A QUESTIONNAIRE ASSESSING THE BURDEN OF FIBROMYALGIA ON PATIENTS DAILY LIVES

    Nov 1, 2008, 00:00

  • PHP41 ANALYSIS OF CLINICAL PHARMACISTS INTERVENTIONS IN A UNIVERSITY TEACHING HOSPITAL IN OMAN

    Nov 1, 2008, 00:00

  • PCN1 THIRD-GENERATION AROMATASE INHIBITORS VS TAMOXIFEN IN THE TREATMENT OF EARLY AND ADVANCED BREAST CANCER- A SYSTEMATIC REVIEW OF RANDOMISED CONTROLLED TRIALS

    Nov 1, 2008, 00:00

  • MH3 COST-EFFECTIVENESS OF LONG-ACTING METHYLPHENIDATE FOR TREATMENT OF ATTENTIONDEFICIT/HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS IN FINLAND- AN EVALUATION BASED UPON A RANDOMIZED CLINICAL TRIAL (RCT)

    Nov 1, 2008, 00:00

  • PDB45 SELF-MANAGEMENT AND PATIENT PERCEPTIONS OF CARE IN RELATION TO HEALTH AND COST-RELATED OUTCOMES IN TYPE 2 DIABETES- A SYSTEMATIC REVIEW

    Nov 1, 2008, 00:00

  • PSY3 PREVALENCE OF METABOLIC ABNORMALITIES AMONG OBESE ADULTS IN KOREA

    Nov 1, 2008, 00:00

  • PDB3 SWITCHING FROM PREMIXED INSULIN TO INSULIN GLARGINE-BASED REGIMEN IMPROVES GLYCAEMIC CONTROL IN PATIENTS WITH TYPE 1 ORTYPE 2 DIABETES- A RETROSPECTIVE PRIMARY CARE-BASED ANALYSIS

    Nov 1, 2008, 00:00

  • PIH12 INPATIENT LENGTH OF STAY AND TOTAL COSTS OF ILLNESSES OF PRESSING CONCERN FOR ASIAN-AMERICAN AND PACIFIC ISLANDERWOMEN IN THE UNITED STATES

    Nov 1, 2008, 00:00

  • PIN26 COST-EFFECTIVENESS OF TREATMENT WITH PEGASYS/COPEGUS IN HIV/HCV CO-INFECTED PATIENTS IN PORTUGAL

    Nov 1, 2008, 00:00

  • PMS70 COST-EFFECTIVENESS OF ETANERCEPT VS. RITUXIMAB IN THE TREATMENT OF ACTIVE RHEUMATOID ARTHRITIS IN COLOMBIA

    Nov 1, 2008, 00:00

  • PMS24 THE COST-EFFECTIVENESS OF SEQUENTIAL USE OF ANTI-TUMOR NECROSIS FACTOR AGENTS IN THE TREATMENT OF RHEUMATOID ARTHRITIS

    Nov 1, 2008, 00:00

  • PCN61 INVASIVE FUNGAL INFECTION (IFI) IN PATIENTS WITH ACUTE MYELOGENOUS LEUKAEMIA (AML) OR MYELODYSPLASTIC SYNDROME (MDS)-TREATMENT COST FROM HOSPITAL PERSPECTIVE

    Nov 1, 2008, 00:00

  • PIN19 PHARMACOECONOMIC EVALUATION OF PARENTERAL ITRACONAZOLE USE IN THE PROPHYLAXIS OF INVASIVE FUNGAL INFECTIONS IN TURKISH SETTING

    Nov 1, 2008, 00:00

  • PCV45 COST-EFFECTIVENESS OF EPLERENONE IN PATIENTS WITH HEART FAILURE AFTER ACUTE MYOCARDIAL INFARCTION

    Nov 1, 2008, 00:00

  • PMH33 COST-UTILITY ANALYSIS OF DULOXETINE VERSUS VENLAFAXINE IN THE MANAGEMENT OF MAJOR DEPRESSION IN PORTUGAL

    Nov 1, 2008, 00:00

  • PND19 AT ALIZUMAB REDUCES RELAPSE-ASSOCIATED COSTS HOSPITALIZATIONS IN PATIENTS WITH RELAPSING MULTIPLE SCLEROSIS

    Nov 1, 2008, 00:00

  • PDB5 GLYCEMIC CONTROL FOLLOWING INITIATION OF INSULIN GLARGINE OR DETEMIR IN PATIENTS WITH TYPE 2 DIABETES MELLITUS- AN ANALYSIS OF ELECTRONIC MEDICAL RECORDS

    Nov 1, 2008, 00:00

  • PRS21 CAN ASTHMA QUALITY OF LIFE QUESTIONNAIRE (AQLQ) DATA FROM DIFFERENT COUNTRIES BE COMBINED FOR ANALYSES?

    Nov 1, 2008, 00:00

  • QL9 DEVELOPMENT AND VALIDATION OF AN ELETRONIC VERSION OF THE HEALTH ASSESSMENT QUESTIONNAIRE DISABILITY INDEX (HAQ-DI)

    Nov 1, 2008, 00:00

  • PMH25 DIRECT COSTS OF UNTREATED COMORBID-INSOMNIA IN AN ELDERLY DEPRESSED MANAGED CARE POPULATION

    Nov 1, 2008, 00:00

  • PUK6 COST-EFFECTIVENESS ANALYSIS OF SACRAL NEUROMODULATION (SNM) FOR PATIENTS WITH OVERACTIVE BLADDER (OAB) IN THE NETHERLANDS

    Nov 1, 2008, 00:00

  • PND28 TRENDS IN RESEARCH INTO CENTRAL NERVOUS SYSTEM DISORDERS- THE INFLUENCE OF AN AGING POPULATION

    Nov 1, 2008, 00:00

  • PDB36 COST-EFFECTIVENESS OF THE ROUX-EN-Y GASTRIC BYPASS SURGERY COMPARED WITH MEDICAL MANAGEMENT FOR TREATMENT OF TYPE 2 DIABETES MELLITUS (T2DM) PATIENTS IN THE USA

    Nov 1, 2008, 00:00

  • PCN89 RACE AND SHARED DECISION MAKING AMONG PROSTATE CANCER PATIENTS, FAMILY MEMBERS AND PHYSICIANS

    Nov 1, 2008, 00:00

  • PCN38 COST-EFFECTIVENESS OF EXTENDED ADJUVANT TREATMENT WITH LETROZOLE IN SWEDEN

    Nov 1, 2008, 00:00

  • PHC14 ORGAN SHORTAGE IN TRANSPLANTATION MEDICINE- WHOSEVALUES AND ON WHAT BASIS SHOULD ORGAN PROCUREMENT BE ORGANISED?

    Nov 1, 2008, 00:00

  • PDB43 ADDING INSULIN GLARGINE TO ORALTHERAPY IN PATIENTS WITHTYPE 2 DIABETES RESULTS IN LONGER PERSISTENCE WITH TREATMENT COMPARED TO NPH INSULIN

    Nov 1, 2008, 00:00

  • PCV66 COST SAVINGS OF CORONARY CT ANGIOGRAPHY VS. CARDIAC CATHETERIZATION TO EVALUATE PATIENTS WITH AN ABNORMAL OR NONDIAGNOSTIC STRESS TEST

    Nov 1, 2008, 00:00

  • PIH6 SYSTEMATIC REVIEW OF ECONOMIC EVALUATION STUDIES IN OBSTETRICS, GYNAECOLOGY AND REPRODUCTIVE MEDICINE

    Nov 1, 2008, 00:00

  • PSY45 PATIENT ACCEPTABLE SYMPTOM STATE (PASS) IN EUROPEAN PATIENTS WITH MODERATE-SEVERE PLAQUE PSORIASIS

    Nov 1, 2008, 00:00

  • PSY22 PROCESS STUDY- A 6-MONTHS COST-CONSEQUENCE ANALYSIS IN CHRONIC PAIN FROM THE SPANISH PERSPECTIVE

    Nov 1, 2008, 00:00

  • PCV36 COST-EFFECTIVENESS AND COST-UTILITY ANALYSIS OF TRITACE COMB (RAMIPRIL/HCTZ) IN TREATMENT OF HYPERTENSION IN POLAND

    Nov 1, 2008, 00:00

  • PND1 INCIDENCE OF INJURY AND COST OF CARE FOR PATIENTS SEEKING EMERGENT CARE FOR EPILEPSY IN A UNITED STATES MANAGED CARE SETTING

    Nov 1, 2008, 00:00

  • PND18 RUFINAMIDE IN THE ADJUNCTIVE TREATMETN OF LENNOX-GASTAUT SYNDROME (LGS)- A COST EFFECTIVENESS ANALYSIS

    Nov 1, 2008, 00:00

  • PCV83 AN EVALUATION OF THE INCREMENTAL CHANGE IN THE INCIDENCE OF CARDIOVASCULAR EVENTS AND RELATED COSTS WITH THE ADDITION OF FIXED-DOSE NIACIN EXTENDED-RELEASE AND SIMVASTATIN THERAPY TO THE MANAGED CARE FORMULARY

    Nov 1, 2008, 00:00

  • PMS37 A MICROSIMULATION-BASED COST-UTILITY ANALYSIS OF RITUXIMAB (MABTHERA ) IN PATIENTS WITH RHEUMATIC ARTHRITIS IN SPAIN

    Nov 1, 2008, 00:00

  • PMC17 VALIDITY OF ELECTRONIC PRECRIPTION CLAIMS RECORDS- A COMPARISON OF ELECTRONIC PBM CLAIMS RECORDS WITH PHARMACY PROVIDER DERIVED RECORDS

    Nov 1, 2008, 00:00

  • PIH13 ASSESSING THE INCREASED MATERNAL AND NEONATAL HEALTH CARE COSTS ASSOCIATED WITH PREECLAMPSIA

    Nov 1, 2008, 00:00

  • PHC7 COST-EFFECTIVENESS OF RIVAROXABANVERSUS ENOXAPARIN FORTHROMBOPROPHYLAXIS AFTER TOTAL HIP REPLACEMENT IN CANADA

    Nov 1, 2008, 00:00

  • PCV54 A EUROPEAN MULTI-COUNTRY COMPARISON OF THE COST-EFFECTIVENESS OF IODIXANOL VERSUS IOHEXOL BASED ON THE RESULTS OF THE NEPHRIC CLINICAL TRIAL

    Nov 1, 2008, 00:00

  • PMH30 ANTIDEPRESSANT THERAPY DURING PREGNANCY- AN INSIGHT ON ITS POTENTIAL HEALTH CARE COSTS

    Nov 1, 2008, 00:00

  • PCN32 ECONOMIC ANALYSIS OF CHEMO RADIOTHERAPY IN HEAD AND NECK CANCER

    Nov 1, 2008, 00:00

  • PCN86 SYMPTOM PREVALENCE IN HORMONE REFRACTORY PROSTATE CANCER (HRPC)

    Nov 1, 2008, 00:00

  • HP4 THE IMPACT OF A MEDICAID EXPANSION TO INCLUDE POPULATION WITH LOW INCOME ON THE PREVENTABLE HOSPITALIZATIONS

    Nov 1, 2008, 00:00

  • PHP29 MICROCOSTING STUDY OF THE DAILY ICU COSTS IN THREE COUNTRIES

    Nov 1, 2008, 00:00

  • PDB59 TREATMENT PATTERNS AND GOAL ATTAINMENT FOR PATIENTS WITH TYPE 2 DIABETES

    Nov 1, 2008, 00:00

  • PIH16 PSYCHOMETRIC PERFORMANCE OF THE CHILDRENS DERMATOLOGY QUALITY OF LIFE INDEX

    Nov 1, 2008, 00:00

  • PCN88 QUESTIONNAIRE OF TREATMENT PREFERENCES IN PATIENTS WITH ADVANCED NON-SMALL CELL LUNG CANCER

    Nov 1, 2008, 00:00

  • Cost-Effectiveness of HIV Screening of Blood Donations in Accra (Ghana)

    Sep 1, 2008, 00:00

  • The Estimation Power of Alternative Comorbidity Indices

    Sep 1, 2008, 00:00

  • An Economic Evaluation of Cetuximab Combined with Radiotherapy for Patients with Locally Advanced Head and Neck Cancer in Belgium, France, Italy, Switzerland, and the United Kingdom

    Sep 1, 2008, 00:00

  • Economic Evaluation of Caspofungin versus Liposomal Amphotericin B for Empiric Antifungal Treatment in Patients with Neutropenic Fever in Italy

    Sep 1, 2008, 00:00

  • Bayesian Meta-Analysis of Multiple Treatment Comparisons- An Introduction to Mixed Treatment Comparisons

    Sep 1, 2008, 00:00

  • Self-Reported Adverse Events after Groin Hernia Repair, A Study Based on a National Register

    Sep 1, 2008, 00:00

  • Variable Access to Clopidogrel in a Harmonized EU Market

    Sep 1, 2008, 00:00

  • Further Validation of an Individualized Migraine Treatment Satisfaction Measure

    Sep 1, 2008, 00:00

  • Lipid Testing among Patients Beginning Statin Therapy in General Practice in the United Kingdom

    Sep 1, 2008, 00:00

  • Using Cost-Effectiveness Analysis to Sharpen Formulary Decision-Making- The Example of Tiotropium at the Veterans Affairs Health Care System

    Sep 1, 2008, 00:00

  • Optimal Cost-Effectiveness Decisions- The Role of the Cost-Effectiveness Acceptability Curve (CEAC), the Cost-Effectiveness Acceptability Frontier (CEAF), and the Expected Value of Perfection Information (EVPI)

    Sep 1, 2008, 00:00

  • Household Demand for Preventive HIV/AIDS Vaccines in Thailand- Do Husbands' and Wives' Preferences Differ?

    Sep 1, 2008, 00:00

  • Quantifying the Decrement in Utility from Perceived Side Effects of Combination Antiretroviral Therapies in Patients with HIV

    Sep 1, 2008, 00:00

  • Using Triple Antiplatelet Therapy in Patients with Non-ST Elevation Acute Coronary Syndrome Managed Invasively- A Cost-Effectiveness Analysis

    Sep 1, 2008, 00:00

  • Economic Evaluation of a Universal Childhood Pneumococcal Conjugate Vaccination Strategy in Ireland

    Sep 1, 2008, 00:00

  • Loss of Treatment Response to Infliximab Maintenance Therapy in Crohn's Disease- A Payor Perspective

    Sep 1, 2008, 00:00

  • Methodological Considerations in Cost of Prostate Cancer Studies- A Systematic Review

    Sep 1, 2008, 00:00

  • Development and Validation of the “Treatment Satisfaction with Medicines Questionnaire” (SATMED-Q)

    Sep 1, 2008, 00:00

  • Cost-Effectiveness of Early versus Late Cinacalcet Treatment in Addition to Standard Care for Secondary Renal Hyperparathyroidism in the USA

    Sep 1, 2008, 00:00

  • The Effect of Atrial Fibrillation on Stroke-Related Inpatient Costs in Sweden- A 3-Year Analysis of Registry Incidence Data from 2001

    Sep 1, 2008, 00:00

  • Parallel Trade of Pharmaceuticals- A Review of Legal, Economic, and Political Aspects

    Sep 1, 2008, 00:00

  • Indirect Costs of Rheumatoid Arthritis in Brazil

    Sep 1, 2008, 00:00

  • Cost-Effectiveness of LTBI Treatment for TB Contacts in British Columbia

    Sep 1, 2008, 00:00

  • How Inducing Covariation in Simulated HDL-C, Triglyceride, and Total Cholesterol Data Affects Framingham Risk Equation Results

    Sep 1, 2008, 00:00
  • «
  • 151
  • 152
  • 153
  • 154
  • 155
  • 156 (current)
  • 157
  • 158
  • 159
  • 160
  • »